

Summary

Preface	1
1. Introduction to the Market Access	3
Mondher Toumi, Szymon Jarosławski	
1.1 Origin of the Market Access Term.....	3
1.2 Healthcare Market Access Definition.....	4
1.3 Market Access Key Concepts	5
1.4 Cultural Specificities of Market Access	8
1.5 Market Access from Payers' Perspective	8
1.6 Market Access Agreements.....	12
1.7 Market Access for Orphan Drugs	13
1.8 Early Advice	16
1.9 Early Access Programs	17
1.10 To Know More	18
2. Market Access in Germany	21
Anke-Peggy Holtorf	
2.1 General Outlook of Healthcare System and Health Policies	21
2.2 Pathways of Market Access (Regulation, Pricing, and Reimbursement)	24
2.3 Mapping and Structure of Decision Makers (Reimbursement/HTA)	32
2.4 Organizations/Physician or Patient Organizations	33
2.5 Challenges and Catalyzers for Market Access.....	33
2.6 Key Success Factors for Market Access in Germany.....	37
2.7 Look-out for Near Future.....	38
2.8 Acknowledgements	38
2.9 References.....	39
3. Market Access in the UK	41
Fatma Betül Yenilmez	
3.1 Introduction	41
3.2 General Outlook of Healthcare System and Health Policies	41
3.3 Pathways of Market Access.....	42

3.4	Mapping and Structure of Decision Makers	44
3.5	Challenges and Catalyzers for Market Access.....	46
3.6	Advances in the Near Future	47
3.7	Bibliography.....	48
4.	Market Access in France	51
	Haythem Ammar	
4.1	General Outlook of Healthcare System.....	51
4.2	Pathways of Market Access (Regulation, Pricing and Reimbursement).....	52
4.3	Mapping and Structure of Decision Makers	54
4.4	Challenges and Catalyzers for Market Access	56
4.5	Acknowledgements	56
4.6	References.....	56
5.	Market Access in Italy.....	59
	Lorenzo Pradelli, Marco Bellone	
5.1	General Outlook of National Health Service and Health Policies	59
5.2	Pathways of Market Access	60
5.3	Mapping and Structure of Decision Makers	70
5.4	Challenges and Catalyzers for Market Access.....	72
5.5	References.....	73
6.	Market Access in Spain	77
	Carme Pinyol, Natividad Calvente, Cristina Espinosa, Toni Gilabert, Carlos Martin (from the ISPOR Regional Spain Chapter)	
6.1	General Outlook of Healthcare System and Health Policies	77
6.2	Pricing and Reimbursement	82
6.3	Mapping and Structure of Decision Makers (Reimbursement/HTA)	86
6.4	Challenges and Catalyzers for Market Access.....	90
6.5	Innovative Mechanisms for Funding, Purchasing and Paying for Drugs.....	91
6.6	Look-out for Near Future.....	96
6.7	Bibliography.....	97
7.	Market Access in Portugal.....	99
	Nuno Silverio	
7.1	Introduction	99
7.2	Healthcare System and Subsystems in Portugal.....	102

7.3	Pathways to Market Access.....	103
7.4	Mapping of Stakeholders.....	116
7.5	Major hurdles	118
7.6	References.....	119
8.	Pharmaceutical Market Access in Denmark, Sweden, and The Netherlands: an Overview	121
	Amir Sharaf	
8.1	Denmark.....	121
8.2	Sweden.....	124
8.3	The Netherlands	127
8.4	References.....	129
9.	Market Access in Japan	133
	Kally Wong	
9.1	Market Background.....	133
9.2	General Outlook of Healthcare System and Health Policies	134
9.3	Structure of Decision Making and Pathways of Market Access.....	139
9.4	Challenges.....	151
9.5	Look-out for Near Future.....	155
9.6	Bibliography.....	156
10.	Market Access in Australia.....	159
	Zafer Çalışkan	
10.1	Background.....	159
10.2	The Healthcare System.....	160
10.3	Medicare	164
10.4	Pathways of Market Access (Regulation, Pricing, and Reimbursement)	164
10.5	Mapping and Structure of Decision Makers	169
10.6	Challenges and Catalyzers for Market Access.....	172
10.7	Good Examples of Successful Market Access Strategies	174
10.8	Look-out for Near Future.....	174
10.9	Bibliography.....	175
11.	Market Access in New Zealand.....	179
	Zafer Çalışkan	
11.1	Background.....	179
11.2	The Healthcare System.....	181

11.3	Pathways of Market Access (Regulation, Pricing, and Reimbursement.....	183
11.4	Mapping and Structure of Decision Makers	187
11.5	Challenges and Catalyzers for Market Access.....	190
11.6	Look-out for Near Future.....	192
11.7	Bibliography.....	192
12.	Pharmaceutical Market in the U.S: a Brief Treatise	195
	Barry A. Bleidt	
12.1	Introduction	195
12.2	History and Development of the Pharmaceutical Industry Market in the U. S.	195
12.3	Pharmaceutical Market Structure	197
12.4	Accessing the American Pharmaceutical Market.....	200
12.5	In Summary	204
12.6	References.....	205
13.	Pharmaceutical Market in Canada: a Brief Treatise.....	207
	Barry A. Bleidt, Annette Vidal	
13.1	Introduction	207
13.2	Canadian Healthcare System	207
13.3	Canadian Drug Market	208
13.4	Drug Approval Process.....	208
13.5	Prescription Drug Pricing.....	209
13.6	Prescription Drug Promotion.....	209
13.7	In Summary	210
13.8	References.....	210
14.	Market Access Hurdles in Developed Countries	213
	Metė Şaylan, Özge Dokuyucu	
14.1	Introduction	213
14.2	Regional Access Hurdles	217
14.3	The Next Challenges.....	220
14.4	In summary	220
14.5	Bibliography.....	221

15. Role of Health Technology Assessment in Pharmaceutical Market Access in Developed Countries.....	223
Rabia Kahveci, Wija Oortwijn, Brian Godman, E. Meltem Koç, Birol Tibet	
15.1 Introduction	223
15.2 History of HTA	224
15.3 HTA and Market Access	225
15.4 HTA, Regulation, Pricing and Reimbursement of Pharmaceuticals.....	226
15.5 How HTA Differs from One Setting to Another	228
15.6 Ongoing Developments Impacting on the Role of HTA to Improve the Managed Entry of New Medicines	234
15.7 References.....	244
16. Impact of the International Reference Pricing on Pharmaceutical Market Access.....	255
Gülpembe Ergin Oğuzhan	
16.1 Definition of International Reference Pricing (IRP)	255
16.2 Basic Mechanism of the IRP	255
16.3 Use of the IRP in Different Countries	255
16.4 Impact of the IRP on the Pharmaceutical Industry.....	256
16.5 Discussion.....	258
16.6 References.....	258
17. General Overview of Value-Based Pricing.....	261
Güvenç Koçkaya	
17.1 The Value-Based Pricing (VBP) Concept	261
17.2 Need for VPB in the Pharmaceutical Industry.....	261
17.3 Stakeholders	262
17.4 Current VBP Practices	263
17.5 Challenges to VBP implementation	263
17.6 Factors Responsible for a Successful VBP Implementation	264
17.7 Conclusion	265
17.8 References.....	265
18. The Role of Patients in Market Access	267
Anke-Peggy Holtorf, Nigel Cook	
18.1 Patients are Active Partners.....	267
18.2 “Nothing About me Without me”	268

18.3	Is Industry Prepared for the Change?	268
18.4	Industry Should be Interested: Improved Commercial Attractiveness Through Patient-centric Product Development.....	270
18.5	What do Patients Expect from the Engagement Activities?	271
18.6	Who is the Patient?	272
18.7	Guidance on Involvement in Industry Research, Regulatory Processes, or HTA.....	273
18.8	Activities for Gaining Patient Insights and for Patient Involvement.....	275
18.9	Up for Discussion	281
18.10	Appendix: Organizations vested in Patient Involvement	282
18.11	References.....	284
19.	The Challenges and Future of Advanced Therapies	289
	Selcen Öztürk	
19.1	Introduction	289
19.2	Recent Developments in Advanced Therapies	290
19.3	Cost-Effectiveness Analysis	293
19.4	Market Access.....	295
19.5	Pricing and Reimbursement Policies.....	296
19.6	Discussion and Perspectives	299
19.7	Acknowledgements	299
19.8	References.....	300
	List of Main Abbreviations	303
	Authors	309